Safety of Short-course of NSAIDs in Pediatric Patients With CKD
Launched by UNIVERSITY OF COLORADO, DENVER · Feb 28, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the safety of using non-steroidal anti-inflammatory drugs (NSAIDs) in children with mild-to-moderate chronic kidney disease (CKD) after surgery. The researchers want to find out if using NSAIDs could increase the risk of acute kidney injury (AKI) in these young patients. They believe that taking NSAIDs won’t actually raise the risk of kidney problems. This study is a small pilot project that will help guide future research with a larger group of patients.
To be eligible for this study, children must be over 18 months old and have a diagnosis of CKD stages 2-3a, which will be confirmed through a specific blood test. However, children with more severe stages of CKD or certain other health conditions, such as those on specific medications or with a history of kidney transplant or diabetes, will not be able to participate. If enrolled, participants will receive NSAIDs post-surgery, and their kidney function will be closely monitored to ensure their safety. The trial is not yet recruiting, but it aims to gather important information to help improve care for children with CKD in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients over 18 months of age
- • diagnosis of CKD stages 2-3a, confirmed by cystatin C laboratory testing within 6 months of surgery
- Exclusion Criteria:
- • diagnosis of CKD stage 1 or 4-5
- • home medications of angiotensin converting enzyme inhibitors (ACEi, such as lisinopril or captopril) or angiotensin receptor blocker (ARB, such as losartan, valsartan) diuretics, or trimethoprim
- • IV contrast in last 30 days
- • PMH of renal transplant, diabetes, hypertension, nephrotic syndrome or heart failure, asthma, or hyperthyroidism
- • history of hyperkalemia
- • recent glucocorticoid exposure
- • procedure for oncologic indications
- • ongoing viral or fungal infection, or chemotherapy
- • allergy to NSAIDs
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Trial Officials
Kyle Rove, MD
Principal Investigator
Children's Hospital Colorado
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported